<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04734028</url>
  </required_header>
  <id_info>
    <org_study_id>PTRG</org_study_id>
    <nct_id>NCT04734028</nct_id>
  </id_info>
  <brief_title>PTRG-DES Consortium</brief_title>
  <acronym>PTRG</acronym>
  <official_title>Platelet Function and genoType-Related Long-term progGosis in DES-treated Patients : A Consortium From Multi-centered Registries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gyeongsang National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korean Society of Interventional Cardiology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gyeongsang National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PTRG-DES consortium is a coalition composed of multi-center, real-world registries&#xD;
      including CAD patients treated with DES in South Korea. From 9 academic registries in Korea,&#xD;
      a total of 13,160 patients were enrolled for this database between July 2003 and August 2018.&#xD;
      The aim of the study was to investigate long-term prognostic implications of platelet&#xD;
      function and genotypes after DES implantation for significant CAD in South Korea.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We enrolled patients treated with DES during DAPT inclduing clopidogrel. In this registry, we&#xD;
      included CAD patients with at least one of VerifyNow test (PRU and ARU) and genotyping. In&#xD;
      this consortium, we tried to find the unique characteristics of East Asians based on platelet&#xD;
      function, genotype and inflammatory markers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 9, 2003</start_date>
  <completion_date type="Actual">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">August 7, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MACCE</measure>
    <time_frame>upto 10 years</time_frame>
    <description>All-cause death, MI, stroke or stent thrombosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>upto 10 years</time_frame>
    <description>BARC type 3-5 bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE1</measure>
    <time_frame>upto 10 years</time_frame>
    <description>CV death, MI and stent thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE2</measure>
    <time_frame>upto 10 years</time_frame>
    <description>CV death, MI, stent thrombosis and revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Each clinical event</measure>
    <time_frame>upto 10 years</time_frame>
    <description>all-cause death, CV death, MI, stroke, stent thrombosis, revascularization or major bleeding</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Clinical event according to gender</measure>
    <time_frame>upto 10 years</time_frame>
    <description>prognostic implications of PFT, genotype and CRP</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical event according to age</measure>
    <time_frame>upto 10 years</time_frame>
    <description>prognostic implications of PFT, genotype and CRP</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical event according to BMI</measure>
    <time_frame>upto 10 years</time_frame>
    <description>prognostic implications of PFT, genotype and CRP</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical event according to anemia</measure>
    <time_frame>upto 10 years</time_frame>
    <description>prognostic implications of PFT, genotype and CRP</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical event according to DM</measure>
    <time_frame>upto 10 years</time_frame>
    <description>prognostic implications of PFT, genotype and CRP</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical event according to CKD</measure>
    <time_frame>upto 10 years</time_frame>
    <description>prognostic implications of PFT, genotype and CRP</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical event according to disease entity (AMI vs. non-AMI)</measure>
    <time_frame>upto 10 years</time_frame>
    <description>prognostic implications of PFT, genotype and CRP</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical event according to LV dysfunction (LV EF)</measure>
    <time_frame>upto 10 years</time_frame>
    <description>prognostic implications of PFT, genotype and CRP</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical event according to complex PCI</measure>
    <time_frame>upto 10 years</time_frame>
    <description>prognostic implications of PFT, genotype and CRP</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical event according to time point post-PCI</measure>
    <time_frame>upto 10 years</time_frame>
    <description>prognostic implications of PFT, genotype and CRP</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">13160</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Clopidogrel, Poor Metabolism of</condition>
  <condition>Platelet Dysfunction</condition>
  <condition>Stent Thrombosis</condition>
  <arm_group>
    <arm_group_label>PTRG-DES registry</arm_group_label>
    <description>After DES implantation, CAD patients were treated with DAPT with clopidogrel and aspirin. During hospitalization, their platelet function, genotype and inflammation biomarker were evaluated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel Tablets</intervention_name>
    <description>DES-treated patients were treated with clopidogrel 75 mg daily and aspirin 100 mg daily</description>
    <arm_group_label>PTRG-DES registry</arm_group_label>
    <other_name>aspirin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Significant CAD patients treated with uneventful DES implantation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consecutive patients at every centre successfully treated with one or more DES&#xD;
             approved by the US FDA or CE mark and who were adequately loaded with clopidogrel were&#xD;
             eligible for enrolment, regardless of patient or lesion complexity.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  the occurrence of a major complication during the procedure or before platelet&#xD;
             function testing, or if bypass surgery was planned after PCI.&#xD;
&#xD;
          -  Any P2Y12 inhibitor other than clopidogrel&#xD;
&#xD;
          -  PCI strategy other than DES&#xD;
&#xD;
          -  Needed oral anticoagulant (e.g. atrial fibrillation)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Do-Sun Lim, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Korea University Anam Hospital, Korea University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gyeongsang National University Changwon Hospital</name>
      <address>
        <city>Changwon</city>
        <state>Gyeongsangnam-do</state>
        <zip>51472</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0040-1718729</url>
    <description>Thrombosis and Haemostasis</description>
  </link>
  <results_reference>
    <citation>Kim HK, Tantry US, Smith SC Jr, Jeong MH, Park SJ, Kim MH, Lim DS, Shin ES, Park DW, Huo Y, Chen SL, Bo Z, Goto S, Kimura T, Yasuda S, Chen WJ, Chan M, Aradi D, Geisler T, Gorog DA, Sibbing D, Lip GYH, Angiolillo DJ, Gurbel PA, Jeong YH. The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease. Thromb Haemost. 2021 Apr;121(4):422-432. doi: 10.1055/s-0040-1718729. Epub 2020 Nov 10.</citation>
    <PMID>33171520</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 28, 2021</study_first_submitted>
  <study_first_submitted_qc>January 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 2, 2021</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asian population</keyword>
  <keyword>VerifyNow assay</keyword>
  <keyword>Genotype</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>If there are the chances of collaboration work, we will share IPD with other groups.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

